Download PowerPoint

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Research Strategic Plan
David W. Niesel, PhD
Chief Research Officer
SVP and Dean GSBS
Research Strategic Plan
Research Planning Task Force
Mariano Garcia-Blanco, MD, PhD
Chair, BMB
Kenneth Ottenbacher, PhD
Professor, Rehab. Sciences
Douglas Tyler, MD
Chair, Surgery
Michael Laposata, MD, PhD
Chair, Pathology
Kathryn Cunningham, PhD
Director, CAR
Allan Brasier, MD
Director, ITS
Nisha Garg, PhD
Professor M&I and Assoc. Dir. IHII
Andrew McNees, PhD, MBA
Director, Research Ops. And Logistics
Toni D’Agostino, MA
Assoc. VP, Research Administration
David W. Niesel, PhD
Chief Research Officer
2
Strategic Management Timeline
•
•
•
•
• Engage Participants
• Drivers of Research
• UTMB Research 2020
Development
• Draft Goals/Objectives
Future Picture Adoption
Goal Adoption
Objective Refinement
Tactical Plan Development
Resource Summary and Prioritization
Implementation Plan
Performance Monitoring & Reporting OnFocus
Strategic Plan Adoption
Adoption Process
Target Setting
Future Picture
Aug
15
Mar
16
June
15
•
•
•
•
•
•
•
•
•
KPI Inventory
Infrastructure
Research Portfolio
Budgeting Process
Center/Institute Assessment
Assessment
Sept
16
Nov
16
• Performance Monitoring and Reporting for FY16
and Preliminary FY17/Beyond
Design and Recommend
Objectives Selected
•
Optimize Clinical Research Infrastructure
•
Expand imaging capabilities and capacity in support of all research
areas
•
Expand interdisciplinary research activity in Infection and Immunology
•
Coordinate selective expansion of informatics development across and
throughout research enterprise
•
Expand interdisciplinary research activity in Neurodysfuntion
•
Expand interdisciplinary research activity in Physical Medicine and
Rehabilitation
•
Expand interdisciplinary research activity in Pulmonary and
Cardiovascular
•
Increase Vaccine Development and Drug discovery activity
Research Enterprise
Top 5 Priority Objectives Resource
Requirements
Objective
Capital
FY17
Optimize Clinical Research Infrastructure
Increase Vaccine development and Drug discovery activity by
$
25
xx% annually through 4FQ17
Coordinate selective expansion of informatics development
$ 200
across and throughout research enterprise
Expand interdisciplinary research activity in Infection and
$ 500
Immunology by 4FQ17
Expand interdisciplinary research activity in Neurodysfuntion
$ 4,200
by 4FQ17
Grand Total
$ 4,925
Research Enterprise
Capital One Time One Time Ongoing Ongoing
New
New Staff
FY18
FY17
FY18
FY17
FY18
Faculty
$
10 $
10 $
477 $
727
3.00
3.20
$
500 $
145 $ 1,120 $
346 $
871
$
250 $
855 $
500 $
500
$ 2,700 $ 5,000
655 $
2.00
$ 1,800 $ 2,350
$ 3,450 $ 6,010 $ 1,785 $ 3,123 $ 4,448
0.50
2.00
2.00
8.70
Why Neurodysfunction?
• Build on existing strengths
• Neuroinfection
• Addiction
Thursday, October 13, 2016
• Pain
Many new projects explore human brain activity.
The National Institutes of Health announced its third round of
grants to support the goals of the Brain Research through
• Traumatic Brain Injury
Advancing Innovative Neurotechnologies (BRAIN) Initiative,
bringing NIH’s total fiscal year 2016 investment to just over $150
• Rehabilitation science
million.
• Alzheimer’s / Cognitive dysfunction
• Alignment with Clinical strategic plan to expand neurosciences
• Ongoing recruitment of new faculty
• Neuroscience
• CAR addiction psychiatrist
Research Enterprise
Research Enterprise
Convergence around
Investments in Neuroscience
National
Neuroscience research is a high Priority for NIH
NIH Brain Initiative (UTS is 1 of 7 universities/systems as partners)
Alzheimer’s Initiative ($638M)
State
UT Brain Program
Chancellors Quantum Leap - Brain Health
UTS Neuroscience and Neurotechnology Research Institute formed
Neuroscience Council (2013)
Neurodysfunction Tactics Resource
Requirements
Objective / Tactic / Sub-Tactic
Expand interdisciplinary research activity in
Neurodysfuntion by 4FQ17
Recruit PI/Co PI Expert(s) (One Time Expense identified for
FY17 is already included in negotiated Start-up
commitments)
Capital
FY17
$
Capital One Time One Time Ongoing Ongoing
New
New Staff
FY18
FY17
FY18
FY17
FY18
Faculty
200 $
200 $ 5,000
Develop economically feasible models to engage physicians
Focus on neurologic dysfunction samples
Create specific seed grant program
Purchase Neuroimaging equipment (fMRI)
Create "Research Marketing" catalog of fundable research
strengths
$ 1,500
Grand Total
$ 4,200 $ 2,700 $ 5,000
Research Enterprise
$ 2,500 $ 2,500
$
$
100 $
100
$
$
$
$
300
500
300
500
$
$
$
$
600
500
600
500
$
100 $
50
- $ 1,800 $ 2,350
2.00
-
2.00
Where do we go from here?
Executive Leadership Group (Institutional Planning)
• Overview of the plan, priorities and recommendations
• Seek partial funding for FY17 and build priorities into FY18 Capital
and Operating budgets
Productivity Enhancement (80% of costs are in people)
• Complete Centers and Institutes evaluation with recommendations
for consolidation and redeployment of resources
• Focused philanthropy
• Evaluation of faculty research funding coverage expectations
• Documentation and establishment of an acceptable threshold for
unfunded research (12% – 35% nationally)
Related documents